Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial

被引：0
|
作者：
Del Prete, Michela [1 ,2 ,3 ,4 ]
Buteau, Francois-Alexandre [1 ,2 ,3 ,4 ]
Beaulieu, Alexis [1 ,2 ,3 ,4 ]
Beauregard, Jean-Mathieu [1 ,2 ,3 ,4 ]
机构：
[1] Univ Laval, Dept Radiol & Nucl Med, Quebec City, PQ, Canada
[2] Univ Laval, Canc Res Ctr, Quebec City, PQ, Canada
[3] Univ Laval, Dept Med Imaging, Div Nucl Med, CHU Quabec, Quebec City, PQ, Canada
[4] Univ Laval, Res Ctr, Oncol Branch, CHU Quabec, Quebec City, PQ, Canada
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷
基金：
加拿大健康研究院;
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
    van Essen, Martijn
    Krenning, Eric P.
    Kam, Boen L. R.
    de Herder, Wouter W.
    Feelders, Richard A.
    Kwekkeboom, Dik J.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) : 383 - 390
  • [32] Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma
    Schneider, Julia R.
    Shatzkes, Deborah R.
    Scharf, Stephen C.
    Tham, Tristan M.
    Kulason, Kay O.
    Buteau, Francois-Alexandre
    Del Prete, Michela
    Chakraborty, Shamik
    Anderson, Todd A.
    Asiry, Saeed
    Beauregard, Jean-Mathieu
    Langer, David J.
    Costantino, Peter D.
    Boockvar, John A.
    OPERATIVE NEUROSURGERY, 2018, 15 (06) : E100 - E109
  • [33] The Tumour Sink Effect on Renal Dosimetry in Patients Treated with 177Lu-Octreotate for Neuroendocrine Tumour: A Potential Role of 68Ga-octreotate-PET/CT for Planning Personalized Peptide Receptor Radionuclide Therapy
    Beauregard, J. M.
    Hofman, M. S.
    Jackson, P.
    Kong, G.
    Hicks, R. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S282 - S283
  • [34] Is it time to bite the dosimetry bullet in patients receiving 177Lu-octreotate PRRT for the management of symptomatic neuroendocrine tumours?
    Ross, E.
    Phillips, J. J.
    Holt, S.
    Buxton-Thomas, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S554 - S554
  • [35] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [36] Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate
    Kamp, Kimberly
    Gumz, Brenda
    Feelders, Richard A.
    Kwekkeboom, Dik J.
    Kaltsas, Gregory
    Costa, Frederico P.
    de Herder, Wouter W.
    ENDOCRINE-RELATED CANCER, 2013, 20 (06) : 825 - 831
  • [37] Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
    Ezziddin, Samer
    Attassi, Mared
    Yong-Hing, Charlotte J.
    Ahmadzadehfar, Hojjat
    Willinek, Winfried
    Gruenwald, Frank
    Guhlke, Stefan
    Biersack, Hans-Juergen
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 183 - 190
  • [38] Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma COMMENT
    Aghi, Manish
    OPERATIVE NEUROSURGERY, 2018, 15 (06) : E109 - E109
  • [39] Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
    Amir Sabet
    Khaled Ezziddin
    Ulrich-Frank Pape
    Karl Reichman
    Torjan Haslerud
    Hojjat Ahmadzadehfar
    Hans-Jürgen Biersack
    James Nagarajah
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 505 - 510
  • [40] Lesion segmentation in Somatostatin Receptor Imaging with 111In-Pentetreotide and 177Lu-Octreotate for Response Monitoring of Neuroendocrine Tumors (net) treated with 177Lu-Octreotate
    Rotger Regi, A.
    Duran Barquero, C.
    Ardila Mantilla, J.
    Lozano Murgas, L.
    Perez-Pascual, R.
    Percovich, J.
    Garcia Centeno, R.
    Blanco Codesido, M.
    Perez Diaz, D.
    Alonso Farto, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S597
12345